Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based on our own technology platforms for the selection of active molecules – antibodies and aptamers.
Pure Biologics also offers commercial partnership options in several areas including early phase biological drug discovery and development, selection and characterization of antibodies and aptamers, as well as protein production, purification and analysis.
Pure Biologics has been operating on the market since 2010. Its headquarters and laboratories are located in Wrocław, Poland. Main areas of activity include biotechnology, biological drug discovery and modern therapeutic solutions based on antibodies and aptamers. Employing almost 100 people, and with a broad portfolio, Pure Biologics is one of Poland’s largest biotechnology companies.
Due to its highly experienced research staff, cutting-edge infrastructure and business acumen, the Company conducts all phases of drug development – from target selection and validation to preclinical studies – on its own.
Additionally, by specializing in the selection of aptamers and antibodies, and in the biophysical analysis of molecular interactions, and the production and analysis of recombinant proteins, Pure Biologics is engaging into partnership with pharmaceutical and biotechnological companies, as well as research institutes all over the world.
Pure Biologics’ therapeutic portfolio includes new immunooncology therapies and non-systemic treatment of autoimmune, neurodegenerative and rare diseases. It is a total of a dozen projects, including five key projects in which we use antibody and aptamer technologies to develop molecules with therapeutic potential.
Pure Biologics engages in commercial collaboration, offering contract research covering three main specialties – aptamers, antibodies and proteins. Our solutions combine a team of highly qualified scientists, the potential of our technology platforms and many years of operational experience.
We bet on stable and balanced development in all key operation areas – our therapeutic portfolio, scientific and business expertise, infrastructure and networking. Our plans envisage achieving financial independence and profits by commercializing therapeutic candidates, allowing us to pursue our next, advanced ideas.